Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

Benzinga · 1d ago
Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.